VRTX · 8-K · 20261102PR000287
Liquidity and Debt Position
VERTEX PHARMACEUTICALS INC / MA · 2026-11-02 · Importance 53 · Surprise 48 · From source text
Cash, cash equivalents, and marketable securities totaled approximately $9.8 billion at September 30, 2026, down from $12.3 billion at December 31, 2025. The balance sheet reported $6.303 billion of cash, cash equivalents, and current marketable securities plus $3.518 billion of long-term marketable securities. Vertex had $4.497 billion of debt at quarter-end, including $1.000 billion of short-term debt and $3.497 billion of long-term debt, compared with no debt at December 31, 2025. The company said it borrowed $4.5 billion under a term loan during the quarter, while operating activities partly offset acquisition and repurchase cash use.
Key facts
- Cash, cash equivalents, and total marketable securities were $9.8 billion at September 30, 2026, compared with $12.3 billion at December 31, 2025. source
- Vertex used $9.0 billion net cash to acquire Crinetics and repurchase Vertex common stock, partially offset by $4.5 billion borrowed under a term loan executed in third-quarter 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | realized | -16.4% | Vertex used $9.0 billion net cash to acquire Crinetics and repurchase Vertex common stock, partially offset by $4.5 billion borrowed under… |
| cash | negative | realized | -9.1% | Cash, cash equivalents, and total marketable securities were $9.8 billion at September 30, 2026, compared with $12.3 billion at December… |